Načítá se...
Immunotherapy for metastatic prostate cancer
Chemotherapy with docetaxel is the standard treatment for men with metastatic prostate cancer, and results in statistically significant improvements in survival, as well as in quality of life. However, the response rate to single-agent docetaxel is approximately 40% to 45%, emphasizing a need for al...
Uloženo v:
| Vydáno v: | Urol Oncol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2007
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4886229/ https://ncbi.nlm.nih.gov/pubmed/18593624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2007.03.029 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|